Myasthenia
gravis is a neuromuscular disease that leads to varying degrees of skeletal
muscle weakness. It is an autoimmune disease resulting from the antibodies
blocking or destroying nicotinic acetylcholine receptors at the junction
between the nerve and muscle, thus preventing nerve impulses rom
triggering muscle contractions. Growth is anticipated in the myasthenia gravis therapeuticspipeline on account of increasing participation of organizations, such as National
Organization for Rare Disorder, that support research and development activities
in field. The unbearable complications such as difficulty in vision,
swallowing, weakness in upper arms and legs and impaired speech are also contributing
to the growth of pipeline therapeutics of myasthenia gravis.
Explore Report at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis
In
August 2005, Debiopharm S.A. entered into a collaboration with DeveloGen AG for
development of PTR-262, a novel peptide drug for the treatment of myasthenia
gravis (MG). PTR-262 is derived from the myasthenogenic epitopes of the
acetylcholine receptor (AChR) alpha-subunit, which specifically arrests the
autoimmune destruction of AChR. Under the terms of the agreement, DeveloGen AG would
receive milestone payments and, upon commercialisation of the product,
royalties based on revenues of Debiopharm S.A., from worldwide sales.
Debiopharm S.A. is an independent company, specialising in oncology,
endocrinology and niche products, whereas, DeveloGen AG is a biopharmaceutical
company, which mainly focuses on development of novel treatments for metabolic disorders.
In March, 2016, Penn centre for innovation had developed therapeutic vaccine
for myasthenia gravis. The advantages of vaccine are long lasting benefits,
potentially permanent protection, prevention as well as reversal of chronic
myasthenia gravis, potent safe and rapid acting.
Some of the companies having a pipeline of myasthenia gravis therapeutics include UCB Pharma, Ltd. Novartis AG, Grifols Therapeutics Inc., Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Inc., DeveloGen AG, Debiopharm S.A.
No comments:
Post a Comment